Bayer HealthCare to present new cancer drug data at AACR 2013

Bayer HealthCare has detailed its plans to present its latest preclinical and early clinical data at the American Association for Cancer Research annual meeting this week.

The company will attend the event in Washington DC to share findings on developmental compounds such as the antibody-drug conjugate Mesothelin-ADC, intended for the treatment of mesothelin-expressing tumours, and the pan-PI3K inhibitor BAY 80-6946.

Preclinical data on the highly selective allosteric AKT1/2 inhibitor, BAY 1125976, will be shared for the first time, while findings on the Ardea Biosciences-licensed drug refametinib are also set to be discussed.

Dr Karl Ziegelbauer, head of Bayer HealthCare's therapeutic research group for oncology/gynaecological therapy, said: "Cancer is a complex disease process and as our understanding of these signaling mechanisms deepens, so does our ability to develop innovative, targeted approaches to combat this disease."

Last month, the company announced the launch of a series of new studies evaluating its established anticoagulant therapy Xarelto's potential application across a range of new indications.